Carvacrol suppresses proliferation and invasion in human oral squamous cell carcinoma

Wei Dai1,2 Changfu Sun1,2 Shaohui Huang1,2 Qing Zhou1,2
1Department of Oromaxillofacial-Head and Neck Surgery, 2Department of Oral and Maxillofacial Surgery, School of Stomatology, China Medical University, Shenyang, Liaoning, People’s Republic of China

Abstract: Carvacrol, a component of thyme oil, as a novel antitumor agent, has been implicated in several types of cancer cells. However, the mechanisms underlying the effect of carvacrol in human oral squamous cell carcinoma (OSCC) remain unclear. Here, we report that carvacrol significantly inhibits tumor cell proliferation, metastasis and invasion, and induces apoptosis in OSCC. Our results demonstrated that the molecular mechanisms of the effect of carvacrol in Tca-8113 induces G1/S cell cycle arrest through downregulation of CDK regulator CCND1 and CDK4, and upregulation of CDK inhibitor P21. Further analysis demonstrated that carvacrol also inhibited Tca-8113 cells’ clone formation in clonogenic cell survival assay. Student’s t-test (two-tailed) was used to compare differences between groups, and the significance level was P<0.01. Then, treatment of Tca-8113 cells with carvacrol resulted in downregulation of Bcl-2, Cox2, and upregulation of Bax. Carvacrol significantly inhibited the migration and invasion of human OSCC cells by blocking the phosphorylation of FAK and MMP-9 and MMP-2, transcription factor ZEB1, and β-catenin proteins’ expression. Taken together, these results provide novel insights into the mechanism of carvacrol and suggest potential therapeutic strategies for human OSCC.

Keywords: carvacrol, proliferation, metastasis and invasion, oral squamous cell carcinoma

Introduction

Tongue cancer, a common malignancy of oral squamous cell carcinoma (OSCC), is poorly responsive to traditional therapies such as radiation therapy and chemotherapy.1,2 Recently, researchers have focused on targeted molecular therapy, immunotherapy, and traditional Chinese medicine monomers.3-5 Our previous studies showed that monoclonal antibody cetuximab is a potential therapeutic strategy for OSCC.6

Carvacrol is a natural isopropyl cresol, which is found in essential oils of the family Lamiaceae, including the genera Origanum and Thymus.7,8 Previous studies have demonstrated that carvacrol has analgesic, antimicrobial, anti-inflammatory, antioxidant, and antiangiogenic properties.9-17 Furthermore, carvacrol was reported to have an anti-proliferative effect on lung, breast, and colon cancer cell lines,16-20 but the effect of carvacrol on OSCC proliferation, apoptosis, and metastasis remains to be determined.

The main purpose of our study was to investigate the feasibility of carvacrol as a noble and strategic treatment modality for OSCC. The main hypothesis is that carvacrol could significantly alter the expression levels of several proteins related to proliferation, apoptosis, and metastasis in OSCC in vitro. The enzyme Cox2 is only produced during inflammation, cell proliferation, and differentiation.21 Studies demonstrated that the decreased expression of Cox2 in cancer cell lines induced cancer cell

Correspondence: Wei Dai
Department of Oromaxillofacial-Head and Neck Surgery, School of Stomatology, China Medical University, No 117 Nanjing North Street, Heping District, Shenyang 110002, Liaoning, People’s Republic of China
Email cmudsaiwei@gmail.com

OncoTargets and Therapy 2016:9 2297–2304

© 2016 Dai et al. This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
apoptosis. The zinc finger transcriptional repressor, ZEB1, inhibits E-cadherin expression. Loss of E-cadherin is associated with tumor invasiveness, metastatic dissemination, and poor prognosis in several solid tumors.\textsuperscript{22} Bcl-2 is a member of anti-apoptotic proteins, which regulate mitochondrial dysfunction. The increased cell apoptosis was accompanied by a decrease in anti-apoptotic Bcl-2 expression and an increase in pro-apoptotic Bax expression.

Here, our data show that carvacrol significantly reduced the proliferation and induced apoptosis by regulating the cell cycle-associated proteins (P21, CCND1 and CDK4) and apoptosis-associated proteins (Cox2, Bcl-2, and Bax). Furthermore, carvacrol suppressed the migration and invasion of Tca-8113 cell lines by inhibiting P-FAK, and reducing \(\beta\)-catenin, ZEB1, and MMP-2/9 expression. Based on obtained results, we conclude that carvacrol plays critical roles in cell cycle, cell invasion, and metastasis signaling pathways.

Materials and methods

Reagents and antibodies

Cell culture reagents were obtained from Gibco-Invitrogen (Thermo Fisher Scientific, Waltham, MA, USA). Carvacrol was purchased from Sigma-Aldrich Co. (St Louis, MO, USA). P21, CDK2, CDK4, CDK6, CCND1, Cox2, Bel-2, Bax, FAK, p-FAK, ZEB1, and \(\beta\)-catenin were purchased from Cell Signaling Technology (Danvers, MA, USA). \(\beta\)-actin was purchased from Beijing Zhongshan Goldenbridge Biotechnology (Beijing, People’s Republic of China) and GAPDH was purchased from ShangHai Kangchen (Shanghai, People’s Republic of China). MMP-2 and MMP-9 were purchased from Santa Cruz Biotechnology Inc. (Dallas, TX, USA).

Cell culture

Human OSCC Tca-8113 and SCC-25 cell lines were obtained from GeneChem Co., Ltd (Shanghai, People’s Republic of China). The cells were cultured in Dulbecco’s Modified Eagle’s Medium (DMEM) (Gibco) plus 10% heat-inactivated fetal bovine serum (FBS), 100 IU/mL penicillin and 100 \(\mu\)g/mL streptomycin at 37°C in a 5% CO\(_2\) incubator. The use of human OSCC cell lines was approved by the ethics committee of the China Medical University.

Treatments

Tca-8113 cells were plated in standard DMEM in 24-well or 6-well dishes, respectively, 24 hours after plating and 8 hours prior to treatment with carvacrol, medium was exchanged with fresh DMEM (no FBS). Cells were treated with the indicated concentration of carvacrol and afterward lysed for Western blotting. Control cultures received the same volume of dimethyl sulfoxide (DMSO).

MTT proliferation assay

Tca-8113 and SCC-25 cells were digested and reseeded in 96-well plates (5\(\times\)10\(^3\)) for cell viability assay. Cells were incubated with 10 \(\mu\)L MTT (10 mg/mL) at 37°C for 4 hours, supernatants were discarded carefully, and 200 \(\mu\)L DMSO was added to solubilize the formazan product for 20 minutes at room temperature. The spectrophotometric absorbance of each sample was measured at 490 nm. All the experiments were repeated in triplicate.

Western blotting analysis

Tca-8113 whole cell extracts were collected in radioimmuno-precipitation assay lysis buffer (50 mM Tris/HCl pH 7.4, 150 mM NaCl, 1% NP-40, 0.25% Na-deoxycholate, 1 mM ethylenediaminetetraacetic acid, and protease inhibitor cocktail). Next, 50 \(\mu\)g of total protein was separated through sodium dodecyl sulfate polyacrylamide gel electrophoresis and transferred to PVDF membranes (GE Healthcare Bio-Sciences Corp., Piscataway, NJ, USA). The membranes were blocked at room temperature for 1 hour in Tris-buffered saline and Tween-20 and 5% fat-free powdered milk, and incubated overnight with specific antibodies at 4°C. After incubation with the primary antibody, the membrane was then incubated with the secondary antibody for 2 hours, and washed in triplicate for 10 minutes in Tris-buffered saline and Tween-20 prior to chemiluminescence detection (GE Healthcare Bio-Sciences Corp.).

Colonies forming assay

Tca-8113 cells were cultured in a 6-well tissue culture plate at 1\(\times\)10\(^4\) cells/well. Cells were grown for 15 days. Colonies were fixed by 4% paraformaldehyde and stained with crystal violet to enable enumeration of colonies.

Cell adhesion assay

Tca-8113 cells were suspended in 0.1% BSA/DMEM (2\(\times\)10\(^4\) cells/500 \(\mu\)L), and seeded onto a fibronectin-coated 24-well Primaria culture dish (500 \(\mu\)L/well). After incubation in a 5% CO\(_2\) incubator for 60 minutes or 100 minutes, non-adherent cells were removed by gently washing twice with 1 mL of phosphate-buffered saline (PBS). Then, following fixation with 500 \(\mu\)L of 4% paraformaldehyde in PBS per well at 4°C for 5 minutes, the adhesive cells were stained with 0.4% Trypan Blue and counted under fluorescent microscopy.

Apoptosis and cell cycle analysis

For apoptosis, the annexin V-FITC apoptosis detection kits (BD Biosciences, San Jose, CA, USA) were used according to the manufacturer’s instructions. Cells were harvested
directly or 24 hours after carvacrol treatment and washed with ice-cold PBS, a FACSScan instrument (BD, Franklin Lakes, NJ, USA) was used to detect apoptosis in cells. The experiment was repeated in triplicate. For cell cycle analysis, cells were trypsinized, washed with PBS, and fixed in 70% ethanol overnight. Cells were centrifuged, washed with PBS, dissolved in 200 µL of propidium iodide, and analyzed.

**Hoechst 33342 staining**

The Tca-8113 cells were washed in triplicate with PBS and fixed in 4% paraformaldehyde for 15 minutes at room temperature. The cells were washed with PBS for 5 minutes and incubated in Hoechst 33342 in the dark for 15 minutes at room temperature.

**Transwell migration and invasion assay**

Migration assays have been described previously in detail. Tca-8113 cells (1 × 10⁶ cells in 100 µL DMEM supplemented with 1% FBS) were placed in the top chamber of transwell migration chambers (8 µM BioCoat Control Inserts, BD). The lower chamber was filled with 600 µL DMEM containing 10% FBS. Matrigel invasion assays were performed using modified Boyden chambers with polycarbonate Nucleopore membrane. Pre-coated filters (6.5 mm in diameter, 8 µm pore size, Matrigel 100 µg/cm²) were rehydrated with 100 µL medium. Then, 1 × 10⁶ cells in 100 µL serum-free DMEM supplemented with 1% BSA were placed in the upper part of each chamber, whereas the lower compartments were filled with 600 µL DMEM containing 10% serum. After incubating for 18 hours at 37°C, unmigrated cells or non-invaded cells were removed from the upper surface of the transwell membrane with a cotton swab, and migrated cells on the lower membrane surface were fixed, stained, photographed, and counted under high-power magnification.

**Statistical analysis**

All statistical analyses were performed using the SPSS 16.0 statistical software program (SPSS Inc., Chicago, IL, USA). Data were presented as the mean ± standard deviation from at least three separate experiments. The statistical analysis correlation of data between groups was checked for significance by Student’s t-test (two-tailed). Differences with P<0.05 were considered significant.

**Results**

**Carvacrol inhibits cell proliferation in human OSCC**

The chemical structure of carvacrol is a chemical compound 5-isopropyl-2-methylphenol with a molecular weight of 150 (Figure 1A).²⁰,²⁴ We examined the effect of carvacrol on the proliferation of human Tca-8113 and SCC-25 cells using an MTT assay. Carvacrol treatment inhibited the proliferation of Tca-8113 and SCC-25 cells in a concentration-dependent manner (Figure 1B and C). Carvacrol had a significant impact on the cell cycle. A significant decrease in the S-phase (from 28.13% to 17.46%) of Tca-8113 cells treated with carvacrol (40 µM) was observed when compared to control group cells (Figure 1D). These results indicate that carvacrol regulates the G1/S phases of the cell cycle in Tca-8113 cancer cells and thus affects their proliferation pattern.

To investigate the mechanisms by which carvacrol inhibited the growth of human Tca-8113 cells, we next examined the expression profile of protein associated with cell proliferation by Western blotting assay. Strikingly, we found that exposure of Tca-8113 to carvacrol (20, 40, and 80 µM) for 24 hours dramatically decreased levels of CCND1 and CDK4 protein expression compared to the DMSO-treated cells, which, in turn, increased the P21 expression in a concentration-dependent manner (Figure 1E). In contrast, expression of CDK2 and CKD6 was not affected under the same experimental conditions (Figure 1F). We further evaluated the effect of carvacrol on Tca-8113 cancer cells using colony formation assay. Colony formation assays showed much less colony formation in the carvacrol-treatment group (40 or 80 µM) compared with the control group (311±21 control group vs 175±17 40 µM group, P<0.01; 311±21 control group vs 142±27, P<0.01) (Figure 1G). These results indicated that carvacrol suppressed Tca-8113 cellular proliferation. Collectively, these findings indicate that carvacrol inhibits proliferation and may regulate Tca-8113 cancer cells through the reduction of cell cycle protein expression of CCND1 and CDK4 proteins and an increase in P21 levels.

**Carvacrol induces Tca-8113 cancer cells’ apoptosis**

The following experiments demonstrated that carvacrol induced apoptosis, and we performed annexin V/propidium iodide staining on carvacrol-treated cells. The results showed that carvacrol could induce apoptosis of Tca-8113 cells in a dose-dependent manner. The cell proliferation inhibition effect was partly due to the promotion of apoptosis (Figure 2A). We therefore assessed the apoptosis-related protein expression of Bcl-2, Bax, and Cox2 in carvacrol-treated Tca-8113 cells.²³ As shown in Figure 2B, carvacrol (0, 10, 20, 40, 60 or 80 µM) enhanced the levels of anti-apoptotic proteins (Bcl-2) in Tca-8113 cells. In addition, in the Tca-8113 cells that were exposed to carvacrol for 24 hours
(0, 10, 20, 40, 60 or 80 µM), the level of proapoptotic proteins Bax and Cox2 decreased. The morphologic changes were examined by Hoechst 33258 staining (Figure 2C). After Tca-8113 cells were treated with 20 µM carvacrol for 24 hours, the apoptotic morphologic changes were observed as compared with the control. In the control group, the nuclei of Tca-8113 cells were round and homogeneously stained while carvacrol-treated cells exhibited evident characteristics of apoptosis. Together, these findings indicate that carvacrol inhibits growth of Tca-8113 cells by inducing apoptosis.

Figure 1 Carvacrol suppresses proliferation in human tongue cancer cells.
Notes: (A) Chemical structure of carvacrol (5-isopropyl-2-methylphenol). Tca-8113 cells (B) and SCC-25 cells (C) were cultured with the indicated concentrations of carvacrol in 96-well plates. After 24 hours (h), the cells were treated with MTT for 4 hours, and absorbance was measured. Results represent the mean ± standard deviation of three experiments done in triplicate. *P<0.05, **P<0.01 vs the Tca-8113 control group. (D) Carvacrol reduces S-phase of Tca-8113 cells compared to control cells. (E, F) Tca-8113 cells were treated with various concentrations of carvacrol (0–80 µM) for 24 hours and then examined for expression of P21, CCND1, CDK4, and the unchanged expression of CDK2 and CDK6 by Western blot analysis. β-actin was used as an internal control for equal amount of total proteins. (G) Colony formation assay of Tca-8113 cells.

Abbreviation: DMSO, dimethyl sulfoxide.
Carvacrol inhibits Tca-8113 cancer cell adhesion ability

To investigate whether carvacrol can influence the ability of Tca-8113 cancer cell invasion, we treated the Tca-8113 cancer cell lines with different concentrations of carvacrol. Carvacrol negatively regulates Tca-8113 cancer cell adhesion to fibronectin compared to control group cells. After 60 minutes’ or 100 minutes’ incubation, when comparing carvacrol-treated Tca-8113 cells with control group cells, carvacrol-treated (80 µM) Tca-8113 cells resulted in a significant decrease in adhesion of approximately 50% or 60% to fibronectin, respectively (Figure 3A, B).

Carvacrol inhibits Tca-8113 cell migration and invasion

Thus, the above results suggested that carvacrol could repress Tca-8113 cancer cell migration and invasion. Moreover, to explore the invasion-related downstream molecules regulated by carvacrol, we checked the expression levels of FAK and p-FAK in carvacrol-treated Tca-8113 cancer...
cells by Western blotting. The results showed that the phosphorylation level of FAK was significantly decreased (Figure 4A). Furthermore, carvacrol treatment decreased the expression of epithelial–mesenchymal transition-related transcription factors β-catenin and ZEB-1 in a dose-dependent manner (Figure 4B, C). Transwell assay was used to determine whether carvacrol affects the invasiveness of Tca-8113 cells. As shown in Figure 4D and E, carvacrol treatment resulted in reduced cell migration and invasion from the top to the bottom chamber compared with the control cells.

Figure 3 Carvacrol inhibited the adherence of Tca-8113 cancer cells.
Notes: Cells’ adherence force was evaluated by adherence assay in 60 minutes (A) or 100 minutes (B). The attached cells were fixed and stained, and ten random fields were counted. Magnification ×200. Scale bars: 200 µM. Also shown is the number of adherent cells from three independent experiments. **P<0.01 using Student’s t-test.

Figure 4 Carvacrol inhibits Tca-8113 cell migration and invasion.
Notes: (A) The expression of p-FAK and FAK proteins was analyzed by Western blotting in carvacrol-treated Tca-8113 cells. (B, C) Expression of β-catenin and ZEB1 in carvacrol-treated Tca-8113 cells. Then, Tca-8113 cells were treated by control or 40 µM of carvacrol for 24 hours, respectively. (D) Transwell assay analyses of the migration or invasion potential of Tca-8113 cells. Magnification ×200. (E) Numbers of migratory or invasive cells (mean ± standard deviation, n=5, “n” means five randomly chosen fields). **P<0.01. (F, G) Tca-8113 cells were treated with 0 to 80 µM of carvacrol for 24 hours. MMP-2 and MMP-9 levels were determined by Western blotting.
suggesting that carvacrol suppresses the migration and invasion capability. Furthermore, MMP-2 and MMP-9 protein expression was dramatically suppressed in Tca-8113 cells treated with carvacrol (Figure 4F, G). We conclude that carvacrol is essential in Tca-8113 cell migration and invasion. Taken together, these results indicated that carvacrol inhibited Tca-8113 cell migration and invasion properties by inhibiting P-FAK and the reduction of β-catenin, ZEB1, and MMP-2/9 expression.

Discussion

Patients with OSCC now have an overall 5-year survival rate of approximately 25%. Natural products have been an advancing development of new anticancer drugs after the advent of molecular biology and chemical compounds to target specific molecules. Carvacrol was the first identified application in cancer therapy, which inhibits growth of myoblast cells even after activation of mutated N-ras oncogene. Our results suggested that carvacrol is a novel, potent, natural anticancer drug for human OSCC. It could suppress human OSCC cancer's proliferation via a series of biological pathways including cell cycle regulation, apoptosis, tumorigenesis, adhesion, and invasion. Accumulating evidence suggests that carvacrol may have therapeutic potential for the prevention and treatment of cancer, including colon cancer, hepatoma, and breast cancer.

Recently, Arunasree reported that carvacrol has an anti-proliferative effect in human metastatic breast cancer cells. Fan et al suggested that carvacrol inhibited the proliferation and migration in human colon cancer cell lines in a dose-dependent manner. Subramaniyan et al indicated that carvacrol exhibited the potential anticancer activity by inhibiting cell proliferation and preventing metastasis in diethylaminoamine-induced hepatocellular carcinogenesis.

In subsequent exploration and analysis, we found that carvacrol effectively inhibits the proliferation of Tca-8113 cells through downregulating the expression of CCND1 and CDK4 and upregulating the expression of P21. Additionally, the MTT assay and colony formation assays illustrated the function of carvacrol in cell growth and proliferation. Generally, apoptosis is closely associated with tumorigenesis. We then evaluated the cell apoptosis of carvacrol-treated Tca-8113 cells by flow cytometry and Western blotting assay. We observed accelerated apoptosis when Tca-8113 cells were treated with carvacrol and an increased ratio of Bax/Bcl-2 was detected in carvacrol-treated Tca-8113 cells, suggesting that carvacrol promotes apoptosis in Tca-8113 cells.

In addition to the effect on cell proliferation and cell apoptosis, we also demonstrated the inhibitory effect on cell migration and invasion of carvacrol on OSCC cells. OSCC is an aggressive disease and a large majority of cancer deaths result from local metastases and distant sites beyond the primary tumor, which are poorly controlled by surgery. FAK is an important protein tyrosine kinase involved in cancer cell invasion and metastasis. In this study, we found that carvacrol could inhibit activation of FAK activity, suggesting that carvacrol inhibits FAK signaling pathways. Our results showed that carvacrol significantly suppressed the migratory and invasive ability of Tca-8113 cancer cells parallel with downregulation of ZEB1 and β-catenin proteins. Then, we found that carvacrol treatment dose-dependently downregulated MMP-2/9 proteins’ expression.

In summary, carvacrol, a natural anticancer agent, was identified to be capable of inhibiting OSCC cell behaviors including proliferation, migration, and invasion. However, these results warrant further testing in experimental models in vivo, and the present findings do support the conception that carvacrol may be a novel approach for the treatment of OSCC patients.

Acknowledgments

This work has been supported by grants from the National Natural Science Foundation of China (numbers 81301835, 81372337, 31201053) and the National Natural Science Foundation of Liaoning Province (number 2015020528). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Disclosure

The authors have no conflicts of interest to disclose.

References


